Bausch + Lomb (BLCO) vs Embecta (EMBC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bausch + Lomb (BLCO) has outperformed Embecta (EMBC) over the past year, gaining 18.3% versus a loss of 57.1%. Bausch + Lomb is the larger company by market cap ($6.19 billion vs $334.9 million), about 18.5 times the size. On valuation, Embecta trades at a lower forward P/E (3.4x vs 15.6x for Bausch + Lomb).
Embecta pays a dividend yielding 7.78%, while Bausch + Lomb does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLCO | EMBC |
|---|---|---|
| Share price | $17.34 | $5.91 |
| Market cap | $6.19B | $334.86M |
| 1-day change | +0.93% | -0.67% |
| YTD return | +1.52% | -50.25% |
| 1-year return | +18.28% | -57.11% |
| P/E ratio (TTM) | — | 4.02 |
| Forward P/E | 15.57 | 3.35 |
| EPS (TTM) | $-0.49 | $1.47 |
| Dividend yield | 0.00% | 7.78% |
| Annual dividend | $0.00 | $0.46 |
| Revenue (latest FY) | $5.10B | — |
| Revenue growth (YoY) | +6.47% | — |
| Net income (latest FY) | $-360.00M | — |
| Operating margin | 2.22% | — |
| Net margin | -7.06% | — |
| 52-week high | $18.92 | $14.91 |
| 52-week low | $13.77 | $2.77 |
| Distance from 52-week high | -8.33% | -60.36% |
| Analyst consensus | buy | none |
| Avg. price target upside | +11.82% | -32.32% |
| Average volume | 392.81K | 1.38M |
| Shares outstanding | 357.17M | 56.66M |
| Employees | 13,000 | 1,850 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bausch + Lomb is about 18.5 times larger than Embecta by market value ($6.19B vs $334.86M).
- BLCO has outperformed EMBC by 75.4 percentage points over the past year.
- Embecta offers a meaningfully higher dividend yield (7.78% vs 0.00%).
About Bausch + Lomb
BLCO stock →Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Healthcare · Medical Instruments & Supplies · 13,000 employees
About Embecta
EMBC stock →Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Healthcare · Medical Instruments & Supplies · 1,850 employees
BLCO vs EMBC FAQ
Which is bigger, Bausch + Lomb or Embecta?
Bausch + Lomb (BLCO) is larger, with a market capitalization of $6.19B compared with $334.86M for Embecta (EMBC).
Which stock has performed better over the past year, BLCO or EMBC?
BLCO returned +18.28% over the past 12 months, compared with -57.11% for EMBC (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bausch + Lomb or Embecta?
Embecta pays a dividend yielding 7.78%, while Bausch + Lomb does not currently pay a regular dividend.
Are Bausch + Lomb and Embecta in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.